Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Higher demand and volume growth for Lilly’s key growth drugs like Emgality, Jardiance, Olumiant, Taltz, and Verzenio are likely to have provided top-line support in the first quarter, driven by ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share.